This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Bayer Intellectual Property Gmbh. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Dagmar Kubitza: Innovator in Thromboembolic Disorder Treatment
Introduction
Dagmar Kubitza is a prominent inventor based in Ratingen, Germany. She has made significant contributions to the field of blood coagulation, particularly in the prevention and treatment of thromboembolic disorders. Her innovative approach has the potential to improve patient outcomes in this critical area of healthcare.
Latest Patents
Dagmar Kubitza holds a patent for a method of treating thromboembolic disorders. The patent, titled "Prevention and treatment of thromboembolic disorders," describes a method of administering a direct factor Xa inhibitor in oral dosage form to patients. This method involves a once-daily administration, which is particularly beneficial for patients in need of effective treatment. The factor Xa inhibitor is characterized by a plasma concentration half-life indicative of a bid or tid administration interval, specifically 10 hours or less.
Career Highlights
Dagmar Kubitza is associated with Bayer Intellectual Property GmbH, where she continues to work on innovative solutions in the medical field. Her expertise in blood coagulation has positioned her as a key figure in the development of new therapeutic methods.
Collaborations
Throughout her career, Dagmar has collaborated with notable colleagues, including Son-Mi Park and Frank Misselwitz. These collaborations have further enhanced her research and development efforts in the field of thromboembolic disorders.
Conclusion
Dagmar Kubitza's contributions to the treatment of thromboembolic disorders exemplify her dedication to innovation in healthcare. Her work not only advances medical science but also holds promise for improving patient care.